Carbon-14 labeled API manufacturing

The development of new drugs is a challenging compromise between time/cost projections and safety/efficacy profiles. Every day lost in the development of a successful drug leads to a direct loss in revenue for the pharmaceutical or biotechnology company.
Carbon-14 labeled API and IMP requirements for Phase 0/I to Phase III mass balance and micro-dosing clinical trials can be met by contract manufacturing in compliance with MHRA and FDA Phase I cGMP guidelines. The short supply and escalating price of carbon-14 labeled building blocks has emphasized the demand for robust synthetic methodologies to incorporate the carbon-14 label efficiently into the API, and outsourcing to a CMO specializing in handling these challenges is a cost-effective approach.
This article published in the Winter 2012/13 edition of Drug Discovery World looks at these challenges and identifies further advantages of outsourcing these services to a CMO, from drug discovery stage to marketing.

View Resource

Please complete this form to view the Article

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies